01—Abstract
Summary
Summary of the 8-K filed February 12, 2025. Cited figures are marked; the original filing is the authoritative source.
CVS Health reported fourth-quarter and full-year 2024 results that were sharply weaker on profitability even as top-line revenue grew.
Total revenues rose 4.2% to $97.7 billiona in the quarter and 4.2% to $372.8 billion for the year, but GAAP diluted EPS fell to $1.30 (from $1.58) in Q4 and to $3.66 (from $6.47) for the full year, while Adjusted EPS dropped to $1.19 in Q4 (from $2.12) and to $5.42 for the year (from $8.74). The decline was driven overwhelmingly by the Health Care Benefits segment, which swung to an adjusted operating loss of $439 million in Q4 and posted only $307 million of adjusted operating income for the full year versus $5.6 billion in 2023. The medical benefit ratio rose from 86.2% to 92.5% for the year, reflecting higher utilization, the unfavorable impact of lower Medicare Advantage star ratings for the 2024 payment year, and higher Medicaid acuity.
The Health Care Benefits segment also recorded a $885 millionb favorable prior-year reserve development, which partly cushioned results. Outside of insurance, the Pharmacy & Consumer Wellness segment grew revenue but saw margin pressure, and the Health Services segment saw revenue decline 7.1% on the loss of a large client and continued pricing concessions. Full-year restructuring charges rose to $1.18 billion, including a store impairment tied to planned 2025 store closures, and the company recorded a $100 million opioid litigation charge.
Operating cash flow fell to $9.1 billionc from $13.4 billion. Management guided 2025 GAAP diluted EPS to $4.58 to $4.83 and Adjusted EPS to $5.75 to $6.00, with operating cash flow of approximately $6.5 billion, implying further earnings pressure relative to 2024 Adjusted EPS. For investors, the key takeaway is that the investment case now hinges on the recovery of Health Care Benefits margins rather than on top-line growth.
The 2025 guidance embeds a substantial step-down in cash generation and earnings, so the credibility of management's medical cost trend assumptions, Medicare Advantage star rating recovery, and Medicaid acuity normalization will be central to the stock's trajectory. The quarter also included a $491 milliond gain on early debt extinguishment, which helped GAAP results but is excluded from Adjusted EPS.
02—Key points
Key Highlights
- Revenue grew 4.2% to $372.8 billion for FY2024 and 4.2% to $97.7 billion in Q4, driven by Health Care Benefits and Pharmacy & Consumer Wellness, offset by a decline in Health Services.
- Full-year Adjusted EPS fell 38% to $5.42 from $8.74, and GAAP diluted EPS fell 43% to $3.66 from $6.47, with Q4 Adjusted EPS down to $1.19 from $2.12.
- Health Care Benefits swung to an adjusted operating loss of $439 million in Q4 2024 and adjusted operating income of only $307 million for FY2024, versus $5.6 billion in 2023; the MBR rose 630 bps to 92.5% for the year.
- Medicare Advantage star rating declines, rising utilization, and higher Medicaid acuity were the primary drivers of the Health Care Benefits deterioration, partly offset by $885 million of favorable prior-year claims development.
- Operating cash flow fell to $9.1 billion from $13.4 billion, and 2025 guidance calls for approximately $6.5 billion.
- 2025 guidance sets GAAP diluted EPS at $4.58 to $4.83 and Adjusted EPS at $5.75 to $6.00, implying a further earnings decline from 2024 levels.
- Restructuring charges rose to $1.18 billion for FY2024, including store impairments tied to planned 2025 retail closures, and a $100 million opioid litigation charge was recorded; a $491 million gain on early debt extinguishment boosted GAAP results.
03—Questions
Frequently Asked Questions
Why did CVS's earnings decline so sharply in 2024 despite revenue growth?
The decline was concentrated in the Health Care Benefits segment, where medical costs rose faster than premiums. The MBR increased from 86.2% to 92.5% for the year, driven by higher utilization, the unfavorable effect of lower Medicare Advantage star ratings for the 2024 payment year, and higher Medicaid acuity following the resumption of eligibility redeterminations. Segment adjusted operating income fell from $5.6 billion to $307 million, which overwhelmed growth elsewhere.
What is the difference between GAAP EPS and Adjusted EPS, and why does it matter here?
GAAP diluted EPS for FY2024 was $3.66, while Adjusted EPS was $5.42. Adjusted EPS excludes amortization of intangible assets ($1.61 per share), restructuring charges ($0.93), acquisition-related costs, the opioid charge, and the debt extinguishment gain, among other items. The gap is large this year because restructuring and amortization were substantial, so investors should evaluate both measures and the reconciliation provided in the release.
What does the 2025 guidance imply for investors?
Management guided to 2025 Adjusted EPS of $5.75 to $6.00, which is below the 2024 level of $5.42 only at the high end, and to GAAP EPS of $4.58 to $4.83, below 2024's $3.66 only in a relative sense; operating cash flow is expected to be about $6.5 billion, down from $9.1 billion. The guidance therefore depends on margin recovery in Health Care Benefits, and results will hinge on whether medical cost trends and Medicare Advantage star ratings improve as planned.
Were there one-time items that affected the reported results?
Yes. GAAP results were boosted by a $491 million gain on early extinguishment of debt tied to the December 2024 tender offer and by $206 million of net realized capital gains in Q4. They were reduced by $1.18 billion of full-year restructuring charges, including store impairments associated with planned 2025 closures, and a $100 million opioid litigation charge. Investors should note that these items are excluded from Adjusted EPS.
What is the outlook for the Health Services and Pharmacy segments?
Health Services revenue fell 7.1% for FY2024, primarily from the loss of a large client and continued pharmacy price concessions, and its adjusted operating income declined 0.9%. Pharmacy & Consumer Wellness revenue grew 6.6%, but its adjusted operating income fell 3.2% for the year due to reimbursement pressure and weaker front-store volume. The release does not provide specific segment guidance for 2025, so these trends should be monitored alongside the Health Care Benefits recovery.
04—Continue